US 7,541,440 B2
	Chimeric, human and humanized anti-granulocyte antibodies and methods of use
David M. Goldenberg, Mendham, N.J. (US); Hans J. Hansen, Picayune, Miss. (US); and Shui-on Leung, Shatin (Hong Kong Special Administrative Region of the People's Republic of China, The)
Assigned to Immunomedics, Inc., Morris Plains, N.J. (US)
Filed on Sep. 29, 2003, as Appl. No. 10/672,278.
Claims priority of provisional application 60/414341, filed on Sep. 30, 2002.
Prior Publication US 2007/0183970 A1, Aug. 09, 2007
Int. Cl. C12P 21/08 (2006.01); C07K 16/00 (2006.01); C07K 17/00 (2006.01); C07K 17/14 (2006.01); A61K 39/00 (2006.01); A61K 39/395 (2006.01)

U.S. Cl. 530—387.3  [530/387.1; 530/391.1; 424/133.1; 424/141.1; 424/181.1; 424/183.1]

24 Claims

1. A chimeric or humanized MN-3 antibody or fragment thereof that binds NCA90 comprising the MN-3 light chain CDR sequences CDR1 (RSSQSIVHSNGNTYLE, SEQ ID NO:1), CDR2 (KVSNRFS, SEQ ID NO:2) and CDR3 (FQGSHVPPT, SEQ ID NO:3) and the MN-3 heavy chain CDR sequences CDR1 (NYGMN, SEQ ID NO:4), CDR2 (WINTYTGEPTYADDFKG, SEQ ID NO:5) and CDR3 (KGWMDFNSSLDY, SEQ ID NO:6).